title: Hyperfractionated radiation therapy and 5-fluorouracil, cisplatin, and mitomycin-C (+/- granulocyte-colony stimulating factor) in the treatment of patients with locally advanced head and neck carcinoma.
abstract: BACKGROUND
  The authors had previously reported preliminary results of a treatment regimen of concurrent hyperfractionated radiation therapy and chemotherapy in patients with locally advanced head and neck carcinoma that demonstrated both feasibility and high local control. In an attempt to reduce acute mucosal and hematologic toxicity, granulocyte-colony stimulating factor (G-CSF) was added during the second phase of this study.
  
  
  METHODS
  Seventy patients (53 with Stage IV and 17 with Stage III disease) were entered between May 1988 and June 1995 into a Phase I/II trial of concurrent radiation therapy (74.4 gray (Gy) total dose; 1.20 Gy twice daily), 5-fluorouracil (1000 mg/m2/24 hours for 72 hours), and cisplatin (50 mg/m2) for 3 cycles with the addition of mitomycin C (8 mg/m2) in Cycle 2. G-CSF was added after the initial entry of 34 patients.
  
  
  RESULTS
  At a median follow-up of 41 months (range, 12-80 months), 44 patients were alive with a projected median overall survival of 54 months. Grade 3/4 mucositis, observed in 65% of patients, was equally prevalent and prolonged in both G-CSF-treated (+) and G-CSF-naive (-) patients. Grade 3/4 leukopenia was present in 45% and 36% of G-CSF- and G-CSF+ patients, respectively. The 3-year locoregional control and cause specific survival rates were 68% and 75%, respectively.
  
  
  CONCLUSIONS
  This regimen was feasible and effective but caused severe mucositis. No benefit was derived from the addition of G-CSF. This regimen deserves further modification to reduce acute mucositis toxicity yet maintain the high locoregional control rate.
authors.affiliation: Department of Radiation Oncology, Sylvester Cancer Center, University of Miami School of Medicine, Florida, USA.
authors.forename: A A
authors.initials: AA
authors.lastname: Abitbol
authors.forename: K S
authors.initials: KS
authors.lastname: Sridhar
authors.forename: A A
authors.initials: AA
authors.lastname: Lewin
authors.forename: J G
authors.initials: JG
authors.lastname: Schwade
authors.forename: W
authors.initials: W
authors.lastname: Raub
authors.forename: A
authors.initials: A
authors.lastname: Wolfson
authors.forename: C
authors.initials: C
authors.lastname: Gonzalez-Angulo
authors.forename: A
authors.initials: A
authors.lastname: Adessa
authors.forename: W J
authors.initials: WJ
authors.lastname: Goodwin
authors.forename: A M
authors.initials: AM
authors.lastname: Markoe
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005240:Feasibility Studies; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D015999:Multivariate Analysis; D016016:Proportional Hazards Models; D011882:Radiotherapy, High-Energy / Q000009:adverse effects; D018709:Statistics, Nonparametric; D016019:Survival Analysis
chemical_list: D016179:Granulocyte Colony-Stimulating Factor; D016685:Mitomycin; D002945:Cisplatin; D005472:Fluorouracil